Nearly 600,000 bottles of blood pressure medication have been recalled due to cancer-causing impurities, exposing millions of Americans to potential carcinogens.
Story Snapshot
- Teva Pharmaceuticals recalled 580,000 bottles of prazosin hydrochloride due to nitrosamine contamination.
- Multiple blood pressure medications, including losartan, valsartan, and quinapril, have been recalled since 2018 for carcinogenic impurities.
- FDA classifies nitrosamine compounds as probable human carcinogens but advises patients not to stop medications abruptly.
- Manufacturing oversight failures have exposed millions of patients to unnecessary cancer risks over seven years.
Massive Recall Affects Hundreds of Thousands of Patients
Teva Pharmaceuticals and Amerisource Health Services issued a nationwide recall of over 580,000 bottles of prazosin hydrochloride after discovering nitrosamine impurities during routine testing.
The recalled medication treats high blood pressure and enlarged prostate symptoms, affecting patients who rely on these drugs for essential health management. This latest recall is just the latest example of contaminated blood pressure medications reaching American patients despite regulatory safeguards.
The contamination involves nitrosamine compounds, specifically N-nitroso impurities that form during drug manufacturing or storage processes. These chemical impurities have been classified as probable human carcinogens by the International Agency for Research on Cancer.
The discovery occurred during expanded testing protocols implemented after previous contamination incidents revealed widespread problems in pharmaceutical manufacturing quality control systems.
Seven Years of Contaminated Medications Expose Regulatory Failures
The blood pressure medication contamination crisis began in July 2018 when the FDA announced NDMA contamination in valsartan, triggering the first major recall. Since then, multiple manufacturers have recalled losartan, irbesartan, quinapril, and combination drugs containing these active ingredients.
Pfizer recalled Accupril and Accuretic in 2022 after discovering contamination with N-nitroso-quinapril, demonstrating that the problem extends across major pharmaceutical companies and multiple drug classes.
The pattern reveals systematic failures in manufacturing oversight, particularly for drugs produced overseas, where quality control standards may be less stringent.
These recalls have affected millions of patients who trusted that their prescribed medications met basic safety standards. The contamination was discovered through routine testing, raising concerns about how many other drugs may contain similar impurities that haven’t yet been detected.
Blood pressure medicine recalled over high levels of cancer-causing chemical https://t.co/TNzj7G5Crg pic.twitter.com/kM9T0MER1b
— New York Post (@nypost) October 30, 2025
Health Risks and Patient Safety Concerns Mount
Nitrosamine impurities pose long-term cancer risks through chronic exposure, though the exact level of risk remains under investigation. Harvard Health notes that while nitrosamines exist naturally in low levels in food and water, the higher concentrations found in contaminated medications may significantly increase cancer risk over time.
The Moffitt Cancer Center emphasizes that NDMA exposure represents a serious health threat that requires immediate regulatory action to protect patients.
Nearly 590,000 bottles of blood pressure medication have been recalled after tests found potential cancer-causing impurities, according to the FDA. Patients are urged not to stop taking their medicine without first talking to their doctor. https://t.co/I6G69w2HhF
— FOX21 News (@FOX21News) November 1, 2025
The FDA advises patients not to discontinue their blood pressure medications abruptly, as uncontrolled hypertension poses immediate health risks that may outweigh the long-term cancer concerns.
However, this guidance places patients in an impossible position where they must choose between immediate cardiovascular risks and potential future cancer development. Healthcare providers are working to transition patients to uncontaminated alternatives, but supply disruptions have complicated these efforts and increased treatment costs.
Sources:
PMC – Hypertension Treatment Evolution
ABC News – Blood Pressure Medication Recall
Harvard Health – More Blood Pressure Medication Recalls
CBS News – Blood Pressure Drug Recall Cancer
Moffitt Cancer Center – FDA Recalls Blood Pressure Meds
Cardiometabolic Health – Carcinogens in Blood Pressure Medications
